# US 2026/0125443 A1 · Fusion protein comprising follicle stimulating hormone and antigen-binding fragment to serum albumin and compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125443 A1
- Document ID: US20260125443A1
- Status: Published application
- Kind: A1
- Application number: 19/118,074
- Filed: 2023-10-04
- Published: 2026-05-07
- Earliest claimed: 2022-10-04
- Assignees: AprilBio Co., Ltd.
- Applicants: Aprilbio Co., Ltd.
- Inventors: Sang Hoon CHA
- Web page: https://patentgrep.com/patent/US20260125443A1

## CPC

- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61P 5/26: Androgens
- A61P 15/02: for disorders of the vagina
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- C07K 16/18: against material from animals or humans
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/55: Fab or Fab'
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to a fusion protein including a follicle stimulating hormone and an antigen-binding fragment to serum albumin and a use thereof. Accordingly, a recombinant fusion protein, which includes an antigen-binding fragment that binds to serum albumin and a human follicle stimulating hormone linked to the antigen-binding fragment, and a long-acting human follicle stimulating hormone formulation including the recombinant fusion protein as an active ingredient are provided.

## Claims

### Claim 1

A recombinant fusion protein comprising (a) a human follicle stimulating hormone (hFSH) comprising an hFSH alpha subunit and an hFSH beta subunit and (b) an antigen binding fragment (Fab) that binds to serum albumin.

### Claim 2 (depends on 1)

The recombinant fusion protein of claim 1, wherein the hFSH alpha subunit and the hFSH beta subunit are linked to terminal regions of the Fab.

### Claim 3 (depends on 1, 2)

The recombinant fusion protein of claim 1 or 2, wherein the hFSH alpha subunit and the hFSH beta subunit are independently linked to a terminus of the heavy chain constant 1 domain and a terminus of the light chain constant domain of the Fab.

### Claim 4 (depends on 1, 2, 3)

The recombinant fusion protein of any one of claims 1-3, wherein the hFSH alpha subunit and the hFSH beta subunit are independently linked by a linker to a terminus of a heavy chain constant 1 domain and a terminus of a light chain constant domain of the Fab.

### Claim 5 (depends on 1, 2, 3, 4)

The recombinant fusion protein of any one of claims 1-4, wherein the hFSH alpha subunit is linked to a terminus of the light chain constant domain and the hFSH beta subunit is linked to a terminus of the heavy chain constant 1 domain of the Fab.

### Claim 6 (depends on 4, 5)

The recombinant fusion protein of claim 4 or 5, wherein the linker comprises 1 to 50 amino acids.

### Claim 7 (depends on 6)

The recombinant fusion protein of claim 6, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOS:16, 70-85, and 88.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The recombinant fusion protein of any one of claims 1-7, wherein the hFSH alpha subunit comprises an amino acid sequence having at least 90% identity to SEQ ID NO:1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The recombinant fusion protein of any one of claims 1-8, wherein the hFSH alpha subunit comprises an amino acid sequence of SEQ ID NO:1.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The recombinant fusion protein of any one of claims 1-9, wherein the hFSH beta subunit comprises an amino acid sequence having at least 90% identity to SEQ ID NO:4.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The recombinant fusion protein of any one of claims 1-10, wherein the hFSH beta subunit comprises an amino acid sequence of SEQ ID NO:4.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The recombinant fusion protein of any one of claims 1-11, wherein the Fab comprises
a heavy chain comprising a heavy chain variable domain comprising
(a) a heavy chain complementarity determining domain 1 (CDR1) comprising the amino acid sequence of SYGIS (SEQ ID NO:22),
a heavy chain complementarity determining domain 2 (CDR2) comprising the amino acid sequence of WINTYSGGTKYAQKFQG (SEQ ID NO:23), and
a heavy chain complementarity determining domain 3 (CDR3) comprising the amino acid sequence of LGHCQRGICSDALDT (SEQ ID NO:24);
(b) a heavy chain CDR1 comprising the amino acid sequence of SYGIS (SEQ ID NO:22),
a heavy chain CDR2 comprising the amino acid sequence of RINTYNGNTGYAQRLQG (SEQ ID NO:25), and
a heavy chain CDR3 comprising the amino acid sequence of LGHCQRGICSDALDT (SEQ ID NO:24);
(c) a heavy chain CDR1 comprising the amino acid sequence of NYGIH (SEQ ID NO:26),
a heavy chain CDR2 comprising the amino acid sequence of SISYDGSNKYYADSVKG (SEQ ID NO:27), and
a heavy chain CDR3 comprising the amino acid sequence of DVHYYGSGSYYNAFDI (SEQ ID NO:28);
(d) a heavy chain CDR1 comprising the amino acid sequence of SYAMS (SEQ ID NO:29),
a heavy chain CDR2 comprising the amino acid sequence of VISHDGGFQYYADSVKG (SEQ ID NO:30), and
a heavy chain CDR3 comprising the amino acid sequence of AGWLRQYGMDV (SEQ ID NO:31);
(e) a heavy chain CDR1 comprising the amino acid sequence of AYWIA (SEQ ID NO:32),
a heavy chain CDR2 comprising the amino acid sequence of MIWPPDADARYSPSFQG (SEQ ID NO:33), and
a heavy chain CDR3 comprising the amino acid sequence of LYSGSYSP (SEQ ID NO:34); or
(f) a heavy chain CDR1 comprising the amino acid sequence of AYSMN (SEQ ID NO:35),
a heavy chain CDR2 comprising the amino acid sequence of SISSSGRYIHYADSVKG (SEQ ID NO:36), and
a heavy chain CDR3 comprising the amino acid sequence of ETVMAGKALDY (SEQ ID NO:37); and
a light chain comprising a light chain variable domain comprising
(g) a light chain CDR1 comprising the amino acid sequence of RASQSISRYLN (SEQ ID NO:38),
a light chain CDR2 comprising the amino acid sequence of GASRLES (SEQ ID NO:39), and
a light chain CDR3 comprising the amino acid sequence of QQSDSVPVT (SEQ ID NO:40);
(h) a light chain CDR1 comprising the amino acid sequence of RASQSISSYLN (SEQ ID NO:41),
a light chain CDR2 comprising the amino acid sequence of AASSLQS (SEQ ID NO:42), and
a light chain CDR3 comprising the amino acid sequence of QQSYSTPPYT (SEQ ID NO:43);
(i) a light chain CDR1 comprising the amino acid sequence of RASQSIFNYVA (SEQ ID NO:44),
a light chain CDR2 comprising the amino acid sequence of DASNRAT (SEQ ID NO:45), and
a light chain CDR3 comprising the amino acid sequence of QQRSKWPPTWT (SEQ ID NO:46);
(j) a light chain CDR1 comprising the amino acid sequence of RASETVSSRQLA (SEQ ID NO:47),
a light chain CDR2 comprising the amino acid sequence of GASSRAT (SEQ ID NO:48), and
a light chain CDR3 comprising the amino acid sequence of QQYGSSPRT (SEQ ID NO:49);
(k) a light chain CDR1 comprising the amino acid sequence of RASQSVSSSSLA (SEQ ID NO:50),
a light chain CDR2 comprising the amino acid sequence of GASSRAT (SEQ ID NO:48), and
a light chain CDR3 comprising the amino acid sequence of QKYSSYPLT (SEQ ID NO:51); or
(1) a light chain CDR1 comprising the amino acid sequence of RASQSVGSNLA (SEQ ID NO:52),
a light chain CDR2 comprising the amino acid sequence of GASTGAT (SEQ ID NO:53), and
a light chain CDR3 comprising the amino acid sequence of QQYYSFLAKT (SEQ ID NO:54).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The recombinant fusion protein of any one of claims 1-12,
wherein the heavy chain variable domain comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:37, and
wherein the light chain variable domain comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:52, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:54.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The recombinant fusion protein of any one of claims 1-13, wherein the heavy chain variable domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO:55, 56, 57, 58, 59, or 60.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The recombinant fusion protein of any one of claims 1-14, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:60.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The recombinant fusion protein of any one of claims 1-15, wherein the light chain variable domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO:61, 62, 63, 64, 65, 66, or 67.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The recombinant fusion protein of any one of claims 1-16, wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:67.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The recombinant fusion protein of any one of claims 1-17, wherein the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO:55, 56, 57, 58, 59, or 60, and the light chain variable domain comprises an amino acid sequence of SEQ ID NO:61, 62, 63, 64, 65, 66, or 67.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The recombinant fusion protein of any one of claims 1-18, wherein the heavy chain constant domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO:68.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The recombinant fusion protein of any one of claims 1-19, wherein the light chain constant domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO:69 or 91.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The recombinant fusion protein of any one of claims 1-20, wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:6 and a light chain comprising the amino acid sequence of SEQ ID NO:91.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The recombinant fusion protein of any one of claims 1-21, wherein the Fab comprises a heavy chain constant 1 domain comprising the amino acid sequence of SEQ ID NO:68 linked to the heavy chain variable domain; and a light chain constant domain comprising the amino acid sequence of SEQ ID NO:69 or 91 linked to the light chain variable domain.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A nucleic acid encoding the recombinant fusion protein of any one of claims 1-22.

### Claim 24 (depends on 23)

An expression vector comprising the nucleic acid of claim 23.

### Claim 25 (depends on 24)

A cell transformed with the expression vector of claim 24.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A composition comprising the recombinant fusion protein of any one of claims 1-22 and a carrier.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A pharmaceutical composition comprising the recombinant fusion protein of any one of claims 1-22 and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 26, 27)

A kit comprising the composition of claim 26 or 27 and a label comprising instructions for a use.

### Claim 29 (depends on 27)

A method of inducing superovulation of a subject in need thereof, comprising applying the pharmaceutical composition of claim 27 to in vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), intracytoplasmic sperm injection (ICSI), or in vitro fertilization.

### Claim 30 (depends on 27)

A method of treating anovulation, hypogonadism, or polycystic ovary syndrome in a subject in need thereof, comprising administering the pharmaceutical composition of claim 27 to the subject.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the composition is administered subcutaneously or intramuscularly to the subject.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A long-acting human follicle stimulating hormone (hFSH) composition comprising the recombinant fusion protein of any one of claims 1-22 as an active ingredient.

### Claim 33 (depends on 32)

The long-acting hFSH formulation of claim 32, wherein the long-acting hFSH formulation is applied to in vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), intracytoplasmic sperm injection (ICSI), or in vitro fertilization, to induce superovulation of a subject.

### Claim 34 (depends on 33)

The long-acting hFSH formulation of claim 33, wherein the long-acting hFSH formulation is used for treatment of anovulation, hypogonadism, or polycystic ovary syndrome.

### Claim 35 (depends on 33)

The long-acting hFSH formulation of claim 33, wherein the long-acting hFSH formulation is administered subcutaneously or intramuscularly.
